Denali Therapeutics Inc. (DNLI) Misses Q4 EPS by 6c

Denali Therapeutics Inc. (NASDAQ: DNLI) reported Q4 EPS of ($0.86), $0.06 worse than the analyst estimate of ($0.80).

For earnings history and earnings-related data on Denali Therapeutics Inc. (DNLI) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Sharon AI surges premarket; New Oriental gains, Medline slips
• Investing.com’s stocks of the week